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Edited by Jesus AvilaAbstract Tetrahydrobiopterin (BH4)-responsive phenylalanine
hydroxylase (PAH) deﬁciency is a recently recognized variant
of phenylketonuria, with a probable multifactorial molecular ba-
sis. In this study we have investigated the eﬀect of BH4 on PAH
gene expression in human hepatoma. Our results show that in-
creased BH4 levels result in an enhancement of PAH activity
and PAH protein, due to longer turnover rates, while PAH
mRNA levels remain unchanged. This was conﬁrmed for mutant
PAH proteins (A309V, V388M and Y414C) associated to in vivo
BH4 responsiveness, validating previous studies. We can con-
clude that there is no eﬀect of the cofactor on PAH gene tran-
scription, probably being the chemical chaperone eﬀect of BH4
stabilizing mutant PAH proteins the major underlying mecha-
nism of the response.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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chaperon1. Introduction
Tetrahydrobiopterin ((6R)-L-erythro-5,6,7,8-tetrahydrobi-
opterin, BH4) is the natural cofactor of phenylalanine hydrox-
ylase (PAH), an hepatic enzyme that catalyzes the
hydroxylation of L-Phe to L-Tyr and which is defective in
the autosomal recessive disorder phenylketonuria (PKU) [1].
The accumulation of L-Phe in body ﬂuids can be eﬀectively
avoided by classical dietary therapy preventing neurological
damage. In addition, supplementation with high doses of the
cofactor can be an eﬀective therapy for a group of PKU pa-
tients [2]. Many studies conducted worldwide have recently
demonstrated that there is a high proportion of patients (60–
70%), who respond positively to a BH4 loading test [3–5]
and several reports have begun to appear proving the eﬃcacy
of long-term treatment with BH4 [6–9].
Examination of the BH4-responsive patients’ genotypes
shows a high genetic heterogeneity, although some mutations
have been repeatedly associated to the response. In vitro
expression data have shown that only a few of these mutations
correspond to KM mutants having a slightly decreased aﬃnityAbbreviations: BH4, (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin; PAH,
phenylalanine hydroxylase; PKU, phenylketonuria; DAHP, 2,4-dia-
mino-6-hydroxypyrimidine
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doi:10.1016/j.febslet.2006.02.005for BH4, and for other mutants stabilization by BH4 was ob-
served [10,11]. In vivo, in the liver of patients with BH4 deﬁ-
ciencies, reduced PAH activity and/or protein have been
reported [12,13]. This already suggested that BH4 concentra-
tion may be an important regulatory factor in maintaining
the steady-state levels of PAH. Similar results were also ob-
served in transgenic mice deﬁcient in cofactor biosynthesis
[14,15]. In transgenic mice with a complete or partial deﬁciency
in 6-pyruvoyltetrahydropterin synthase (PTPS), the rate of
PAH activity and protein levels increased with BH4 content
without aﬀecting PAH mRNA levels, apparently ruling out
an eﬀect on gene expression [15]. However, for inducible nitric
oxide synthase (iNOS), which also requires BH4 as essential
cofactor, a post-transcriptional stabilization of iNOS mRNA
by BH4 has been described in several cell types [16,17].
In this study we sought out to analyze the eﬀect of BH4 lev-
els on PAH gene expression in human hepatoma cells, where
PAH and the enzymes responsible for the BH4 biosynthetic
pathway are naturally expressed. Precursors and inhibitors of
the intracellular synthesis pathway, which involve three en-
zymes (GTP cyclohydrolase I, GTPCH-1, PTPS and sepiap-
terin reductase, SR) [18,19], were used to modulate BH4 levels.
The results of increasing BH4 levels in hepatoma cells dis-
card an eﬀect of the cofactor on PAH gene transcription,
and conﬁrm a chaperon-like eﬀect of BH4 lowering PAH deg-
radation rate. The stabilization eﬀect was also demonstrated
for three mutant PAH proteins associated to BH4 response
and which were tagged with a FLAG epitope and transfected
into hepatoma cells for measurement of protein steady state
levels in the presence of increased levels of BH4.2. Materials and methods
2.1. Materials
Sepiapterin was obtained from Dr. B. Schircks Laboratories (Jona,
Switzerland). Actinomycin D, puromycin, dicumarol and 2,4-diamino-
6-hydroxypyrimidine (DAHP) were from Sigma–Aldrich. Cell culture
medium and fetal calf serum (FCS) were from Gibco-BRL. Monoclo-
nal antibody anti PAH (PH8) was from Pharmingen. Anti-FLAG M2
antibody was from Sigma. The secondary antibody (antimouse Ig con-
jugated with horseradish peroxidase) was from Santa Cruz. The Jetpei
transfection reagent was obtained from Polyplus transfections.
2.2. Cell culture and transfection
Human hepatoma cells Hep3B were cultured under standard condi-
tions in minimum essential medium supplemented with 1% glutamine,
10%FCS and antibiotics. Cells were supplemented with 100 lM
sepiapterin or 100 lM dicumarol or 10 mM DAHP for the times indi-
cated. For transient expression of PAH-FLAG constructs, 4 · 106 cells
were plated in T-75 ﬂasks and transfected with Jetpei following theblished by Elsevier B.V. All rights reserved.
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DNA mixture was removed and replaced with fresh medium supple-
mented or not with the various reagents. PAH-FLAG proteins were
analyzed after 48 h.
2.3. Determination of intracellular biopterin
Hep3B cells treated with the indicated agents were harvested by
trypsinization and washed with phosphate-buﬀered saline. Pellets were
resuspended in 100 mM Na-HEPES (pH 7.0) and lysed by freeze–
thawing. After centrifugation to remove cell debris, the supernatant
(total cell extract) was used for ﬂuorimetric determination of total bio-
terin [3].
2.4. Determination of PAH activity
After treatment with the various reagents for 48 h, PAH activity in
cell extracts obtained as described above was measured for 30 min at
25 C as conversion of L-Phe to L-Tyr [10] and after elimination of
aminoacids using Ultrafree-MC 10000 NMWL ﬁlters. The amount
of L-Tyr formed was measured by HPLC and ﬂuorimetric detection.
2.5. Protein analysis
Wild-type PAH protein or transfected PAH-FLAG proteins in
Hep3B cells were detected by Western blotting using commercial
monoclonal antibodies (anti PAH Ph8 or anti-FLAG M2, respec-
tively), anti-mouse-Ig hoseradish peroxidase conjugate and the en-
hanced chemiluminiscence detection system ECL (Amersham). For
determination of protein turnover, after treatment with the various re-
agents for 48 h, protein synthesis was stopped by addition of 10 lg/ml
puromycin to the culture medium and cells were harvested at deﬁned
time points up to 10 h and analyzed by Western blotting. Relative pro-
tein amounts were determined by densitometric analysis and expressed
as percentage of residual protein.
2.6. mRNA analysis
Total cellular RNA was isolated using the SV Total RNA Isolation
Kit (Promega). For relative PAH mRNA quantiﬁcation, the Taqman
Gene Expression assay Hs00609359 (Applied Biosystems) was used.
RNA was retrotranscribed using the Archive kit and PCR ampliﬁedPA
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Fig. 1. Eﬀect of precursors and inhibitors of the BH4 biosynthetic pathway
PAH protein in hepatoma cells. After supplementation with sepiapterin (100
PAH activity, PAH mRNA and PAH protein content were measured in cellu
at least three experiments. SEP, sepiapterin; BH4, precursor; DIC, dicumarowith the Taqman Universal PCRMaster Mix, all from Applied Biosys-
tems. The real-time PCR and analysis were performed in an ABIP-
RISM 7900HT Genetic Analyzer. Ampliﬁcation eﬃciency and
sample to sample variation were normalised by monitoring glyceralde-
hyde phosphate dehydrogenase (GAPDH) mRNA or 18S rRNA.
2.7. Cloning into pFLAG vector
PAH cDNA was ampliﬁed from pMAL-PAH expression vector [20]
using primers 5 0-TTTTGCGGCCGCGATGTCCACTGCGGTCCT-
GG-3 0 and 5 0-AAAAGTCGACGGCTTTACTTTATTTTCTGGAG-
3 0, designed with SalI and NotI restriction sites at their 5 0 ends, respec-
tively, to allow directed cloning into the pFLAG-CMV vector (Sigma).
The in-frame fusion of amino-terminal FLAG peptide with the PAH
protein was conﬁrmed by sequencing performed with BigDye Termina-
tor v.3.1 mix (Applied Biosystems) and analyzed by capillary electro-
phoresis on an ABI Prism 3700 Genetic Analyzer (Applied
Biosystems). Mutations were introduced into the wild-type construct
using the Quickchange mutagenesis kit (Stratagene) and conﬁrmed
by sequencing analysis.3. Results
Human hepatoma cells were used as cellular model to deter-
mine the eﬀect of BH4 on PAH gene expression. Sepiapterin
was used as precursor of the intracellular BH4 biosynthetic
pathway and dicumarol or DAHP as inhibitors of enzymes in-
volved in BH4 synthesis (of SR and GTPCH-1, respectively) to
reduce BH4 levels.
Pterin analysis in Hep3B cells cultured in standard conditions
revealed levels of 15.4 pmol/mg of total biopterin. After 48 h
supplementation with 100 lM sepiapterin in the culture med-
ium, biopterin levels increased to 4601 ± 1633 pmol/mg, while
treatment with dicumarol (100 lM) or DAHP (10 mM) re-
duced total biopterin to undetectable levels (Fig. 1A). A similar
increase or decrease in biopterin levels after supplementation(n
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Fig. 2. Analysis of PAH protein turnover in hepatoma cells. After
incubation with sepiapterin for 48 h, translation was stopped with
puromycin (10 lg/ml) and PAH protein in cells harvested up to 10 h
was analysed by Western blot analysis (upper panel). The lower panel
shows the representation of the results as a semilogarithmic plot of
relative PAH protein obtained after densitometric analysis of Western
blot autoradiograms. Shown is the mean of two independent exper-
iments. The inner box shows the estimated half-lives of PAH protein in
each condition.
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Fig. 3. Steady-state levels of wild-type and mutant PAH-FLAG
proteins transiently expressed in hepatoma cells in the presence or not
of sepiapterin as BH4 precursor. PAH-FLAG proteins were detected
in cellular extracts using anti-FLAG antibodies and quantiﬁed by
densitometric analysis. The data are the mean ± S.D. of at least three
experiments.
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ﬁrmed in all subsequent experiments regarding PAH activity,
protein or mRNA.
Supplementation with sepiapterin produced a 4-fold
enhancement in PAH activity in hepatoma cells. Treatment
with dicumarol abolished PAH activity completely while
DAHP unexpectedly increased it (Fig. 1B).
The potentiation of PAH activity with sepiapterin could be
due to BH4 playing a regulatory role at the level of protein
or mRNA expression. To test this hypothesis, we ﬁrst exam-
ined PAH mRNA levels in hepatoma cells cultured in standard
medium alone or supplemented for 48 h with sepiapterin, dicu-
marol or DAHP. Quantitation of PAH mRNA levels revealed
no signiﬁcant diﬀerences between culture conditions, with only
a slight reduction in mRNA levels in dicumarol treated cells
(Fig. 1C). However, direct observation of the cells with dicu-
marol before harvesting showed generalised cell death which
could explain this result.
The inﬂuence of BH4 on PAH activity observed in sepiap-
terin treated cells could thus be ascribed to the post-transcrip-
tional level. We next examined PAH protein levels by Western
blot analysis, which revealed that in sepiapterin-supplemented
cells PAH protein was strongly augmented, correlating with
the increase in PAH activity. In dicumarol treated cells no
PAH was detectable, while with DAHP, PAH protein levels
were increased correlating with the results obtained for PAH
activity (Fig. 1D).
To determine whether BH4 levels were aﬀecting steady-state
protein turnover and taking into account previous evidence of
a stabilization eﬀect of BH4 on PAH proteins [10,11,15], we
measured PAH protein half-life in hepatoma after treatment
with the diﬀerent compounds. Protein synthesis was stopped
with translation inhibitor puromycin (10 lg/ml) and protein
amounts were determined by Western blot at deﬁned time
points up to 10 h (Fig. 2). PAH protein half-life in hepatoma
was estimated at 9.4 h, in line with previous reports in an
in vitro cell-free synthesis system [10,11]. Treatment with
sepiapterin increased PAH half-life 3-fold, conﬁrming that
BH4 may exert a protective eﬀect preventing degradation of
PAH protein.
To validate the results obtained previously in a cell-free syn-
thesis system [10,11] and to provide a rationale for BH4
responsiveness in PKU, the eﬀect of BH4 on previously studied
mutant PAH proteins (A309V, V388M and Y414C) was reas-
sessed in hepatoma. For this purpose, wild-type and mutant
PAH constructs tagged with a FLAG epitope were engineered
in the expression vector pFLAG-CMV. The A309V, V388M
and Y414C mutations had been shown in an in vitro expres-
sion system to be stabilized by BH4 [10,11].
Transfection of the wild-type construct in hepatoma cells re-
sulted in the expression of PAH-FLAG protein detected by
Western blot analysis using anti-FLAG antibody, thus pre-
cluding the detection of endogenous PAH. Estimation of
PAH-FLAG protein half-life was 9.4 h, the same as that ob-
tained with endogenous PAH, showing that the FLAG peptide
does not alter signiﬁcantly the properties of the PAH protein.
Transfection of the mutant constructs A309V, V388M and
Y414C revealed that the steady-state amount of protein is
somewhat reduced compared to wild-type (Fig. 3), in correla-
tion with what had already been reported by expression anal-
ysis in COS cells, indicative of folding defects [20]. Although in
this system we have to take into account the presence of endog-enous PAH protein which could be forming oligomers with the
transfected mutant proteins stabilising them, we sought to ﬁnd
out whether steady-state levels of mutant proteins were in-
creased with sepiapterin. As shown in Fig. 3, in sepiapterin
treated cells, the amount of all three mutant proteins is eﬀec-
tively increased although this eﬀect is minimal for wild-type
PAH-FLAG protein.
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Oral BH4 supplementation in responsive PKU patients is
turning out to be a successful therapy, along with a progressive
relaxation or complete withdrawal from dietary therapy [6–9].
A major issue in the understanding of BH4 responsiveness in
PKU patients is the knowledge of the disease mechanism once
the genetic defect is determined, providing useful information
on which to base therapeutic strategies tailored to each patient.
Experimental evidence has accumulated suggesting the
molecular basis of the response is multifactorial [10,11,15]. A
potential eﬀect of BH4 on PAH gene expression was initially
put forward, although results in transgenic mice deﬁcient for
cofactor biosynthesis do not support this hypothesis [15].
The data obtained in hepatoma concur with the reported
observations. The mRNA analysis rules out transcriptional
regulation or mRNA stabilization by BH4, and corroborates
that PAH is stabilized by increased BH4 levels, resulting in a
net increase in the amount of steady state levels of the enzyme
and thus of the activity. It is not uncommon for protein stabil-
ity to be enhanced by the binding of its cofactor [21–23] and in
recombinant PAH, the binding of BH4 was reported to result
in reduced proteolysis by trypsin [24].
With the present study, we cannot discard an eﬀect of BH4
on translational regulation as has been described for vitamin
B12, cofactor of methionine synthase [25,26]. However, the
stabilization of the PAH protein by BH4 alone may account
for the increase in steady-state levels of PAH protein observed.
The results obtained in hepatoma cells with the inhibitors of
the BH4 biosynthetic pathway are not straightforward. Dicu-
marol and DAHP have been used previously to investigate
cytokine-induced nitric oxide production in endothelial and
smooth muscle cells [16,17,27]. However, at 100 lM, dicuma-
rol reduced drastically hepatoma cell viability and mRNA
analysis showed a large variability even for housekeeping genes
such as GAPDH or 18S rRNA. To circumvent this, we used
DAHP which functions as a BH4 mimetic to engage feedback
inhibition of GTPCH mediated by the GTPCH feedback reg-
ulatory protein (GFRP) [28]. At 10 mM, DAHP results in an
unexpected increase in steady-state levels of PAH protein
and thus of the relative activity, without aﬀecting mRNA lev-
els or protein turnover. This suggests there could be some
unforeseen eﬀect maybe on translation which could account
for the results.
Three mutant proteins (A309V, V388M and Y414C) in-
volved in the in vivo response and previously studied in
the cell-free in vitro synthesis system TnT [10,11] have been
analyzed in hepatoma, which provides a more physiological
milieu correlating with the in vivo situation. The three mu-
tant proteins tagged with a FLAG epitope were found to be
stabilized by increased BH4 levels, conﬁrming previous re-
sults. Wild-type protein did not increase substantially, simi-
lar to what was observed in the TNT system [10,11].
Diﬀerences in expression levels between endogenous PAH
in hepatoma and PAH synthesized in vitro in the TNT sys-
tem or in transient expression under a viral promoter may
account for these results.
The chaperon-like eﬀect of BH4 preventing accelerated deg-
radation is likely not limited to a few PAH proteins, as shown
here, but represents a generalised eﬀect on most missense fold-
ing PAH mutants explaining the high number of mutations
associated to the in vivo response. As it has already been putforward, almost all responsive patients have at least one mis-
sense change resulting in a partially active protein and which
represent mainly folding defects (excluding a few KM mutants)
[29]. The present studies and those performed in transgenic
mice [15,30] ﬁrmly support the notion that the stabilization
of PAH proteins by BH4 is the major mechanism in vivo
responsible for BH4 responsiveness in PKU patients.
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